IP Library › Granted Patent US 10,786,596
Granted Patent B2
US 10,786,596 · App. 16/245,780 · Granted Sep 29, 2020

Powder for achieving hemostasis

Inventors: Gerald Fredrickson (Westford, MA); Amanda L. Smith (Boston, MA); Andrew Pic (Northborough, MA); Sophia Gervasio (Coventry, RI); Lauren Lydecker (Millbury, MA)
Assignee: Boston Scientific Scimed, Inc.
A61L26/0023A61K31/722A61L26/008A61L26/0066A61L31/042A61L31/16A61L2300/232A61L2300/418A61L2300/60A61L2400/04A61M25/09A61M2025/091A61M2202/064A61M2210/1042
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,786,596
App. No.
16/245,780
Filed
Jan 11, 2019
Granted
Sep 29, 2020
Kind
B2
Examiner
SOROUSH, ALI
Art Unit
1617
USPC
424/499
Abstract

In various aspects, the present disclosure pertains to methods of treating or preventing bleeding at a tissue site comprising applying a chitosan powder composition to the tissue site. In various aspects, the present disclosure pertains to chitosan powder compositions for application to a tissue site, where the powder compositions comprise a chitosan salt, a crosslinked chitosan, a derivatized chitosan, or a combination thereof. In various aspects, the disclosure pertains to catheter assemblies, which are preloaded with a chitosan powder composition and which are configured to deliver the chitosan powder composition a tissue site.

Claims (18)

1. A method of treating or preventing bleeding at a tissue site comprising:

applying a chitosan powder composition to the tissue site,

wherein the chitosan powder composition comprises first particles comprising a chitosan salt of an organic mono-acid, a chitosan salt of an organic diacid, or a chitosan salt of a hydroxyacid, admixed with second particles that comprise a crosslinking agent, wherein the crosslinking agent is a derivatized polymer selected from an epoxy derivatized polymer, an acrylate derivatized polymer, or a genipin derivatized polymer, and

wherein the chitosan powder composition is applied to a gastrointestinal tract through an endoscope.

2. The method of claim 1 , wherein the chitosan powder composition is fluidized in a gas to form a fluidized powder and blown onto the tissue site.

3. The method of claim 2 , wherein the gas is CO 2 .

4. The method of claim 2 , wherein the fluidized powder is applied using a catheter and wherein the fluidized powder exits the catheter at a velocity ranging from 15 to 50 m/s.

5. A powder composition for application to a tissue site, the powder composition comprising first particles admixed with second particles that comprise a crosslinking agent that covalently or non-covalently interacts with the first particles upon exposure to moisture, wherein the first particles comprise a chitosan salt and the crosslinking agent is a derivatized polymer selected from an epoxy derivatized polymer, an acrylate derivatized polymer, or a genipin derivatized polymer.

6. A powder composition for application to a tissue site, the powder composition comprising first particles admixed with second particles, the first particles comprising derivatized chitosan selected from chitosan derivatized with a multifunctional aldehyde, chitosan derivatized with unsaturated groups, chitosan derivatized with a multifunctional epoxide, chitosan derivatized with acrylate groups, or thiol-modified chitosan; and the second particles comprising a covalent crosslinking agent; wherein the covalent crosslinking agent is a molecule having a plurality of unsaturated groups when the first particles comprise thiol-modified chitosan.

7. The powder composition of claim 6 , wherein the derivatized chitosan reacts with cysteine groups in tissue upon exposure to moisture.

8. A method of treating or preventing bleeding at a tissue site comprising: applying the powder composition of claim 5 to a gastrointestinal tract through an endoscope.

9. The method of claim 8 , wherein the powder composition is fluidized in a gas to form a fluidized powder composition and blown onto the tissue site.

10. The method of claim 9 , wherein the fluidized powder composition is applied using a catheter and wherein the fluidized powder composition exits the catheter at a velocity ranging from 15 to 50 m/s.

11. A method of treating or preventing bleeding at a tissue site comprising: applying the powder composition of claim 6 to a gastrointestinal tract through an endoscope.

12. The method of claim 1 , wherein the powder composition is fluidized in a gas to form a fluidized powder composition and blown onto the tissue site.

13. The method of claim 12 , wherein the fluidized powder composition is applied using a catheter and wherein the fluidized powder composition exits the catheter at a velocity ranging from 15 to 50 m/s.

14. The powder composition of claim 5 , wherein the crosslinking agent is the epoxy derivatized polymer or the acrylate derivatized polymer.

15. The powder composition of claim 5 , wherein the first particles comprise a chitosan salt of an organic mono-acid or a chitosan salt of an organic diacid.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2019
From: FREDRICKSON, GERALD; SMITH, AMANDA L.; PIC, ANDREW; GERVASIO, SOPHIA; LYDECKER, LAUREN
To: BOSTON SCIENTIFIC SCIMED, INC.
Reel/Frame 047988/0144 →
Continuity (2)
Provisional Application 62616751 · Jan 12, 2018
Related Publication 20190216974A1 · Jul 18, 2019